Was Enobia’s Sale A High Water Mark For Rare Disease Deals?
This article was originally published in Start Up
Alexion’s “hotly contested” purchase of Enobia last December didn’t get much attention, but it marked a watershed year for rare disease drug deals. Will high drug prices, skittish regulators and a gold-rush push by Big Pharma start to sour the sector?
You may also be interested in...
Two former biotech high flyers are up for sale, with Amylin attracting more would-be suitors than Human Genome Sciences. The spectacle of the bidding is great. But did you know that the orphan drug company Alexion is worth more than those two companies combined?
Aegerion is preparing for an advisory committee meeting after submitting its LDL-C lowering oral drug lomitapide to FDA for patients with homozygous familial hypercholesterolemia. The NDA was submitted ahead of that for Isis/Genzyme’s injectable competitor, mipomersen.
Collaboration will create start-up biotechs to advance promising research in orphan indications, but the companies will not take a “cookie cutter” approach to structure or evolution.